Therapeutics News and Research

RSS

New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

A new Duke-NUS-led study has identified a super-potent antibody which requires a minute amount to neutralize the dengue virus.

21 Feb 2015

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC).

20 Feb 2015

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).

20 Feb 2015

Scientists identify promising new therapeutic target for prostate cancer

Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.

20 Feb 2015

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference.

19 Feb 2015

VirMedica acquires assets of TransEngen

VirMedica, a leading provider of technology solutions designed to optimize the commercialization of specialty pharmaceutical products, announced today that VirMedica, Inc. has acquired the assets of TransEngen, Inc. The $15 million dollar financing was led by Nashville-based Petra Capital Partners along with Menlo Park-based HealthQuest Capital.

19 Feb 2015

Pioneering Separations Company Quad Technologies Set To Revolutionize Cell Isolation Following Successful Investment

Quad Technologies Inc (“Quad”), developer of a novel separation technology, has formally announced its entry into the cell separation market.

19 Feb 2015

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine's primary metabolite supports learning and memory by amplifying the action of a primary chemical messenger involved in both, researchers report.

19 Feb 2015

EC grants orphan drug designation to aTyr Pharma's Resolaris for treatment of FSHD

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today the European Commission (EC) has granted orphan drug designation to Resolaris for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

19 Feb 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

President of MD Anderson selected as new fellow of AACR Academy

Ron DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, will be inducted as a new fellow of the American Association for Cancer Research Academy. He joins 10 other cancer leaders in the prestigious academy that recognizes people who have made significant contributions to cancer research.

18 Feb 2015

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Cells lining the intestinal tract form a critical barrier, protecting our bodies from the billions of bacteria living in the gut. Breaches in this barrier are driven largely by a single signaling molecule called tumor necrosis factor (TNF), elevated amounts of which are associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

17 Feb 2015

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

17 Feb 2015

World class drug discovery team launches new company to tackle chronic respiratory disease

Respiratory diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma represent a major unmet medical need and a significant health burden in both the developed and developing world.

16 Feb 2015

TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

Scientists from the Florida campus of The Scripps Research Institute have for the first time discovered a killing mechanism that could underpin a range of the most intractable neurodegenerative diseases such as Alzheimer's, Parkinson's and ALS.

16 Feb 2015

A*STAR's GIS scientists develop new system that can predict treatment targets for cancer

In recent months, several national initiatives for personalized medicine have been announced, including the recently launched precision medicine initiative in the US, driven by rapid advances in genomic technologies and with the promise of cheaper and better healthcare. Significant challenges remain, however, in the management and analysis of genetic information and their integration with patient data.

15 Feb 2015

'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

The new study, published recently in the journal Brain, revealed the mechanism of toxicity of a misfolded form of the protein that underlies prion diseases, such as bovine spongiform encephalopathy (“mad cow disease”) and its human equivalent, Creutzfeldt-Jakob disease.

13 Feb 2015

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Jazz Pharmaceuticals plc announced today that researchers will present data on the use of defibrotide, an investigational medicine being studied in the United States (U.S.) for the treatment of hepatic veno-occlusive disease (VOD), a rare, potentially life-threatening, early complication in patients undergoing hematopoietic stem-cell transplantation (HSCT) therapy.

13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

Scientists find that treating the uninjured side of brain can maximize stroke recovery

To maximize stroke recovery, researchers may want to focus more on ways to support the side of the brain where the injury didn't occur, scientists report.

13 Feb 2015

Therapeutics News and Research

New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

Betaretrovirus may infect patients with primary biliary cirrhosis

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Scientists identify promising new therapeutic target for prostate cancer

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

VirMedica acquires assets of TransEngen

Pioneering Separations Company Quad Technologies Set To Revolutionize Cell Isolation Following Successful Investment

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

EC grants orphan drug designation to aTyr Pharma's Resolaris for treatment of FSHD

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

President of MD Anderson selected as new fellow of AACR Academy

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

World class drug discovery team launches new company to tackle chronic respiratory disease

TSRI scientists discover novel mechanism involved in Alzheimer's, Parkinson's and ALS

A*STAR's GIS scientists develop new system that can predict treatment targets for cancer

'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases

Jazz Pharmaceuticals to present defibrotide results for hepatic VOD at BMT Tandem meetings

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Scientists find that treating the uninjured side of brain can maximize stroke recovery

Advancing therapeutic biopolymer development eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News